MiR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-? B in high-grade serous ovarian carcinoma

64Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Activation of mammalian target of rapamycin (mTOR) signaling pathway is associated with poor prognosis of epithelial ovarian cancer. The TSC1-TSC2 complex is a critical negative regulator of mTOR signaling. Here, we demonstrated that TSC1 was frequently downregulated in high-grade serous ovarian carcinoma (HGSOC) and low TSC1 expression level is associated with advanced tumor stage. We next identified miR-130a to be a negative regulator of TSC1 by targeting its 3'UTR. miR-130a was overexpressed in HGSOC and could drive proliferation and invasion/metastasis of ovarian cancer cells. miR-130a could also attenuate rapamycin/starvation-induced autophagy. Ectopic TSC1 expression could block the effects of miR-130a on cell proliferation, migration and autophagy. Finally, we found that miR-130a expression could be upregulated by inflammatory factors and was transactivated by NF-? B. Therefore, our findings establish a crosstalk between inflammation and mTOR signaling that is mediated by miR-130a, which might have a pivotal role in the initiation and progression of HGSOC.

Cite

CITATION STYLE

APA

Wang, Y., Zhang, X., Tang, W., Lin, Z., Xu, L., Dong, R., … Liu, Z. (2017). MiR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-? B in high-grade serous ovarian carcinoma. Cell Death and Differentiation, 24(12), 2089–2100. https://doi.org/10.1038/cdd.2017.129

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free